I'm LongbridgeAI, I can summarize articles.Revenue: As of FY2025 Q3, the actual value is USD 1.016 B, beating the estimate of USD 869.89 M.
EPS: As of FY2025 Q3, the actual value is USD -0.51, beating the estimate of USD -2.1792.
EBIT: As of FY2025 Q3, the actual value is USD -333 M.
Segment Revenue
- Total Revenue: $1.0 billion for Q3 2025, a 45% decrease from $1.9 billion in Q3 2024, primarily due to a 47% decrease in net product sales, mainly from lower COVID vaccine sales.
- COVID Vaccine Sales: $971 million in Q3 2025, with $781 million from U.S. sales and $190 million from international sales.
- RSV Vaccine Sales: $2 million in Q3 2025.
Operational Metrics
- Net Loss: - $200 million for Q3 2025, compared to net income of $13 million in Q3 2024.
- Cost of Sales: $207 million for Q3 2025, a 60% decrease from Q3 2024, reflecting lower inventory write-downs and reduced unutilized manufacturing capacity.
- Research and Development Expenses: $801 million for Q3 2025, a 30% decrease from Q3 2024, due to investment prioritization and efficiency gains.
- Selling, General and Administrative Expenses: $268 million for Q3 2025, a 5% decrease from Q3 2024.
Cash Flow
- Cash Position: $6.6 billion as of September 30, 2025, down from $7.5 billion as of June 30, 2025, primarily due to seasonal impacts on working capital.
Unique Metrics
- Operating Expenses: Expected to improve by $0.7 billion to a range of $5.2 - $5.4 billion for 2025.
Outlook / Guidance
- Revenue Guidance: Narrowed 2025 projected revenue range to $1.6 - $2.0 billion.
- Year-End Cash Balance: Expected to increase by $0.5 billion - $1 billion to a range of $6.5 - $7.0 billion.
- Cost of Sales for 2025: Expected to be approximately $0.8 to $0.9 billion, lowered from $1.2 billion.